Apollo Hospitals

    APOLLOHOSP
    Pharma
    ₹7,844.00
    Price as of 26 Oct 2026, 4:52 pm IST

    Market cap ₹1.13 L Cr

    P/E
    53.97
    Day range
    ₹7,634.00 – ₹7,844.00
    52-week range
    ₹6,696.50 – ₹9,070.50
    Volume
    4.14 L
    Open
    ₹7,719.00
    Prev close
    ₹7,730.00

    Latest results · Q1 FY27(consolidated)Revenue ₹7,044 Cr+20.6%Profit ₹610 Cr+38.4%Margin 8.7%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter pledge went up

      2.91% of promoter shares pledged, up from 2.49% · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    APOLLOHOSP in NSE indices and F&O

    F&O margin for one lot of APOLLOHOSP (125 shares)

    Research profile

    Composite 58 / 100

    Factor percentiles

    Value27
    Quality52
    Momentum58
    Low volatility95

    Derived metrics

    Earn. yield
    1.9%
    Graham no.
    ₹1,484.18
    vs Graham
    -81.1%
    ROE ÷ P/B
    1.9%
    12-1 mom.
    +13.9%
    Return / vol
    -0.02
    Magic Formula
    #444
    Piotroski
    4/6
    FCF yield
    0.8%
    PEG
    1.61

    Appears in 13 scans

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 67 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.17 L Cr34.525.0214.8%21.0%29.0%0.06+10.5%
    Divi's LaboratoriesDIVISLAB₹2.40 L Cr82.1214.1816.2%22.0%41.0%0.00+27.8%
    Torrent PharmaTORNTPHARM₹1.73 L Cr76.869.3726.8%15.0%33.0%0.77+50.8%
    Zydus LifesciencesZYDUSLIFE₹1.16 L Cr25.864.2020.1%21.0%24.0%0.46+22.0%
    Apollo HospitalsAPOLLOHOSP₹1.13 L Cr53.9711.7322.6%17.0%16.0%0.90+20.6%
    Laurus LabsLAURUSLABS₹1.11 L Cr101.7720.0618.2%18.0%32.0%0.48+29.0%
    CiplaCIPLA₹1.09 L Cr32.493.1411.8%15.0%17.0%0.02+2.3%
    Dr. Reddy's LabsDRREDDY₹1.09 L Cr39.032.6511.6%13.0%20.0%0.19-1.5%
    Sector median₹24,447 Cr41.535.6015.1%17.0%25.0%0.16+20.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 8d ago

    Headlines about Apollo Hospitals from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.

    Key metrics

    P/E (TTM)
    52.8
    EPS (TTM)
    ₹145.21
    Price / Book
    11.90
    ROE (FY26)
    22.6%
    ROCE (latest year)
    17%
    Dividend yield
    0.26%

    Moving averages (NSE)

    20-day
    ₹8,049.48
    Price below
    50-day
    ₹8,497.57
    Price below
    200-day
    ₹8,073.57
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +14.9%
    Profit 3Y CAGR
    +33.4%
    Revenue YoY (Jun 2026)
    +20.6%
    Profit YoY (Jun 2026)
    +38.3%
    Operating margin
    16.0%
    Net margin
    8.7%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr2K Cr4K Cr6K Cr8K Cr
    • Revenue
    • Net profit

    Operating margin

    Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Jun 20260%8%16%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • FII
    • Promoter
    • DII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-4K Cr-2K Cr0 Cr2K Cr4K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2.5K Cr5K Cr7.5K Cr10K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 20260x1x2x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹5₹10₹15₹20

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales4,8474,8514,9445,0865,5895,5275,5925,8426,3046,4776,6067,044
    Expenses4,2194,2374,3034,4104,7744,7654,8224,9905,3625,5125,5945,951
    Operating Profit6286146406758167627708529419651,0111,092
    OPM %13%13%13%13%15%14%14%15%15%15%15%16%
    Other Income262937494469725461485462
    Interest111113119116118110115108110113119120
    Depreciation163167190177184185211215218219224235
    Profit before tax379363368430557536516583675682722799
    Tax %34%30%30%27%29%29%20%24%27%24%24%24%
    Net Profit249254258316396379414441494516551610
    EPS in Rs₹16.20₹17.06₹17.65₹21.23₹26.34₹25.89₹27.10₹30.10₹33.19₹34.93₹36.81₹40.39

    From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days50

    +4 days since Mar 2021

    Inventory Days15

    -1 days since Mar 2021

    Days Payable63

    -11 days since Mar 2021

    Cash Conversion Cycle3

    +15 days since Mar 2021

    Working Capital Days-25

    -21 days since Mar 2021

    Strengths, risks & growth

    Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country. Apollo Hospitals has emerged as Asia’s foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models. [1]

    Strengths

    • Company has delivered good profit growth of 76.2% CAGR over last 5 years
    • Company has been maintaining a healthy dividend payout of 17.7%

    Risks

    • Stock is trading at 11.7 times its book value
    • Company might be capitalizing the interest cost

    Compounded Sales Growth

    10 Years
    +15%
    5 Years
    +19%
    3 Years
    +15%
    TTM
    +17%

    Compounded Profit Growth

    10 Years
    +23%
    5 Years
    +76%
    3 Years
    +32%
    TTM
    +34%

    Stock Price CAGR

    10 Years
    +19%
    5 Years
    +13%
    3 Years
    +17%
    1 Year
    -1%

    Return on Equity

    10 Years
    +13%
    5 Years
    +17%
    3 Years
    +18%
    Last Year
    +21%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter28.02%28.02%28.02%28.02%0.00 pp
    FII43.54%42.62%41.49%43.19%+1.70 pp
    DII21.50%22.76%23.72%22.07%-1.65 pp
    Government0.23%0.23%0.23%0.23%0.00 pp
    Public6.71%6.39%6.53%6.49%-0.04 pp

    Filed with NSE for Sept 2026: promoters 28.02%, public 71.98% · XBRL filing

    Analysts & fund holdings

    87%
    87% recommend buy
    30 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E54.0 vs 44.1
    Sector P/B5.53
    Beta0.64

    Who holds the shares, quarter by quarter

    Mutual funds 17.19% (-0.14 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters28.0%
    • Foreign institutions43.2%
    • Mutual funds17.2%
    • Insurance3.8%
    • Other domestic institutions1.1%
    • Retail4.3%
    • Others2.4%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Flexi Cap Fund0.76%0.79%+0.20 pp
    Axis Large Cap Fund0.75%2.91%-0.02 pp
    ICICI Pru Balanced Advantage Fund0.50%0.79%+0.10 pp
    Axis Focused Fund0.47%5.06%-0.18 pp
    SBI Flexicap Fund0.41%2.09%-0.08 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Risk & trend

    From 275 daily sessions to 23 Oct 2026.

    Computed

    Risk

    Volatility (1Y)
    20.0%
    Downside volatility
    18.8%
    Worst 5% of days
    1.8%
    Average of that tail
    2.7%
    Max drawdown (1Y)
    16.2%
    Below its peak
    14.8%

    Against the market

    Beta vs Nifty 50
    0.59
    Correlation
    0.39
    Relative strength (3M)
    -7.5%
    ATR (14)
    2.7%

    Return

    Return 1M
    -12.5%
    Return 3M
    -12.8%
    Return 6M
    +0.9%
    Return 1Y
    -0.4%
    vs 200-day average
    -4.3%

    Momentum

    RSI (14)
    36.8
    MACD histogram
    -15.14
    Stochastic %K
    41.7
    ADX (14)
    36.4
    +DI / −DI
    12.5 / 29.0
    Money flow index
    25.2

    Participation

    Delivery (20d avg)
    60.5%
    vs its 60-day baseline
    +0.4 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    +1.0%
    52-week position
    41 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 31 Mar 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹894 Cr
    FCF yield
    0.8%
    Cash conversion
    1.43
    Accruals ratio
    -0.038
    Net debt
    ₹7,681 Cr
    Net debt / equity
    0.81
    EV / sales
    4.50
    PEG
    1.61
    Capex intensity
    7.8%
    Revenue CAGR
    18.1%
    Profit CAGR
    33.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    No market trades
    1 buys · ₹0
    2 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    K VISHWESHWAR REDDY
    Promoter · Pledge Creation
    		Pledge2,00,000₹178 Cr26 Aug 2026
    K VISHWESHWAR REDDY
    Promoter · Pledge Release
    		Pledge released1,15,000₹101 Cr20 Aug 2026
    K VISHWESHWAR REDDY
    Promoter · Pledge Creation
    		Pledge81,000₹71.5 Cr19 Aug 2026
    HARSHAD REDDY
    Promoters · Inter-se-Transfer
    		Sell1,10,000₹030 Dec 2025
    KARTHIK ANAND
    Promoters · Inter-se-Transfer
    		Sell1,10,000₹030 Dec 2025
    p vijayakumar reddy
    Promoters · Inter-se-Transfer
    		Buy2,20,000₹030 Dec 2025
    SUNEETA REDDY
    Promoters · Revokation of Pledge
    		Pledge released1,50,000₹112 Cr18 Nov 2025
    PCR INVESTMENTS LIMITED
    Promoters · Revokation of Pledge
    		Pledge released23,00,000₹181 Cr17 Oct 2025
    K VISHWESHWAR REDDY
    Promoters · Pledge Creation
    		Pledge70,000₹52.1 Cr30 Sept 2025
    SUNEETA REDDY
    Promoters · Revokation of Pledge
    		Pledge released1,75,000₹138 Cr12 Sept 2025
    K VISHWESHWAR REDDY
    Promoters · Revokation of Pledge
    		Pledge released2,77,946₹220 Cr10 Sept 2025
    SUNEETA REDDY
    Promoters · Revokation of Pledge
    		Pledge released5,75,000₹445 Cr5 Sept 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹10.00

      Dividend - Rs 10 Per Sh

      14 Aug 2026
      ex-date
    • dividend
      ₹10.00

      Interim Dividend - Rs 10 Per Sh

      16 Feb 2026
      ex-date
    • dividend
      ₹10.00

      Dividend - Rs 10 Per Share

      19 Aug 2025
      ex-date
    • dividend
      ₹9.00

      Interim Dividend - Rs 9 Per Share

      14 Feb 2025
      ex-date
    • dividend
      ₹10.00

      Annual General Meeting/Dividend - Rs 10 Per Share

      16 Aug 2024
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      20 Feb 2024
      ex-date
    • dividend
      ₹9.00

      Annual General Meeting/Dividend - Rs 9 Per Share

      18 Aug 2023
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      24 Feb 2023
      ex-date
    • dividend
      ₹11.75

      Annual General Meeting/Dividend - Rs 11.75 Per Share

      18 Aug 2022
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      18 Aug 2021
      ex-date
    • dividend
      ₹2.75

      Annual General Meeting/Dividend - Rs 2.75 Per Share

      17 Sept 2020
      ex-date
    • dividend
      ₹3.25

      Interim Dividend - Rs 3.25 Per Share

      25 Feb 2020
      ex-date
    • dividend
      ₹6.00

      Annual General Meeting/Dividend - Rs 6 Per Share

      12 Sept 2019
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend- Rs 5 Per Share

      12 Sept 2018
      ex-date
    • dividend
      ₹6.00

      Annual General Meeting/Dividend - Rs 6/- Per Share

      7 Sept 2017
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6/- Per Share (Purpose Revised)

      22 Mar 2016
      ex-date
    • dividend
      ₹5.75

      Annual General Meeting/Dividend Rs 5.75 Per Share

      30 Jul 2015
      ex-date
    • dividend
      ₹5.75

      Annual General Meeting And Dividend Rs.5.75 Per Share

      13 Aug 2014
      ex-date
    • dividend
      ₹5.50

      Annual General Meeting And Dividend Rs.5.50 Per Share

      25 Jul 2013
      ex-date
    • dividend
      ₹4.00

      Annual General Meeting/Dividend Rs 4 Per Share

      26 Jul 2012
      ex-date
    • dividend
      ₹3.75

      Annual General Meeting And Dividend Rs.3.75 Per Share

      7 Jul 2011
      ex-date

    Company announcements

    Company Update
    Intimation Of Schedule Of Analyst/ Institutional Investors Meeting

    As per annexure enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    As per annexure enclosed

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Notice Of The Board Meeting

    Apollo Hospitals Enterprise Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve As per annexure enclosed

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) for the period ended 30th September 2026 is enclosed

    Insider Trading / SAST
    Closure of Trading Window

    As per annexure enclosed

    Company Update
    Notice For Transfer Of Shares To IEPF

    as per annexure enclosed

    Others
    Reg. 34 (1) Annual Report.

    Dear Sir, Sub : Submission of Updated Annual Report for FY 2025-26 We refer to the Annual Report of the Company for the financial year ended 31 March 2026, which was submitted to the ....

    Company Update
    Summary Of Proceedings Of AGM And Voting Results

    As per annexure enclosed

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    As per annexure enclosed

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    As per annexure enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    as per annexure enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    As per annexure enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    As per annexure enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    As per annexure enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    As per annexure enclosec

    Filed with BSE (scrip 508869); the last 45 days. Documents open at bseindia.com.

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 13 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Apollo Hospitals: common questions

    Answered from the figures on this page.

    Apollo Hospitals last traded at ₹7,844.00 (NSE, as of 26 Oct 2026). The last session moved it up 1.47%.

    Apollo Hospitals is valued at about ₹1.13 lakh crore (NSE, as of 26 Oct 2026).

    Apollo Hospitals trades at a price-to-earnings ratio of 53.97 (NSE, as of 26 Oct 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Apollo Hospitals has traded between ₹6,696.50 and ₹9,070.50 over the past 52 weeks, to 26 Oct 2026. It is currently 48% of the way up that range.

    Apollo Hospitals (APOLLOHOSP) is classified under Pharma on this site's screener.